Biotech entity
Every one of those 4 sits in a single category, pharma. JPMorgan Chase & Co. is most often covered alongside Weiss Ratings, which appears in 3 of these 4 stories. Each story carries 2 original sources on average, compared with 3.7 for the broader beat in this window.
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 4 sits in a single category, pharma. JPMorgan Chase & Co. is most often covered alongside Weiss Ratings, which appears in 3 of these 4 stories. Each story carries 2 original sources on average, compared with 3.7 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 6.2. That works out to roughly 0.2 stories per week across a 156-day span. We currently track 4 Biotech stories that mention JPMorgan Chase & Co., published between March 6, 2026 and August 8, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 532 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JPMorgan Chase & Co.. Shared-story counts are live from our verified record — not editorial picks.
JPMorgan Disclosure
JPMorgan Chase & Co. reveals its $12.55 million position in the company.
Insider Activity
CEO Serge Saxonov sells 9,632 shares under a standard trading plan.
Syon Capital Entry
Syon Capital LLC discloses a new stake in TXG, adding to institutional support.
Market Momentum
10x Genomics shares trade up 6.4% as market sentiment begins to shift.
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Source: tickerreport.com · themarketsdaily.com
Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Source: Ticker Report · Watch List News
JPMorgan Chase & Co. has established a significant $12.55 million position in 10x Genomics, signaling institutional confidence in the spatial biology leader. This move comes as the biotech tools sector navigates a complex landscape of patent litigation and shifting R&D budgets.
Source: dailypolitical.com · tickerreport.com
JPMorgan Chase & Co. is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
